Cargando…

Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier

In this study, a glycyrrhetinic acid-functionalized mesoporous silica nanoparticle (MSN-GA) was prepared for active tumor targeting. MSN-GA exhibited satisfactory loading capacity for insoluble drugs, uniform size distribution, and specific tumor cell targeting. Glycyrrhetinic acid, a hepatocellular...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Yongjiu, Li, Jingjing, Chen, Huali, Bai, Yan, Zhang, Liangke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476610/
https://www.ncbi.nlm.nih.gov/pubmed/28652738
http://dx.doi.org/10.2147/IJN.S135626
_version_ 1783244621329989632
author Lv, Yongjiu
Li, Jingjing
Chen, Huali
Bai, Yan
Zhang, Liangke
author_facet Lv, Yongjiu
Li, Jingjing
Chen, Huali
Bai, Yan
Zhang, Liangke
author_sort Lv, Yongjiu
collection PubMed
description In this study, a glycyrrhetinic acid-functionalized mesoporous silica nanoparticle (MSN-GA) was prepared for active tumor targeting. MSN-GA exhibited satisfactory loading capacity for insoluble drugs, uniform size distribution, and specific tumor cell targeting. Glycyrrhetinic acid, a hepatocellular carcinoma-targeting group, was covalently decorated on the surface of MSN via an amido bond. The successful synthesis of MSN-GA was validated by the results of Fourier transform infrared spectroscopy, transmission electron microscopy (TEM), and zeta potential measurement. TEM images revealed the spherical morphology and uniform size distribution of the naked MSN and MSN-GA. Curcumin (CUR), an insoluble model drug, was loaded into MSN-GA (denoted as MSN-GA-CUR) with a high-loading capacity (8.78%±1.24%). The results of the in vitro cellular experiment demonstrated that MSN-GA-CUR significantly enhanced cytotoxicity and cellular uptake toward hepatocellular carcinoma (HepG2) cells via a specific GA receptor-mediated endocytosis mechanism. The results of this study provide a promising nanoplatform for the targeting of hepatocellular carcinoma.
format Online
Article
Text
id pubmed-5476610
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-54766102017-06-26 Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier Lv, Yongjiu Li, Jingjing Chen, Huali Bai, Yan Zhang, Liangke Int J Nanomedicine Original Research In this study, a glycyrrhetinic acid-functionalized mesoporous silica nanoparticle (MSN-GA) was prepared for active tumor targeting. MSN-GA exhibited satisfactory loading capacity for insoluble drugs, uniform size distribution, and specific tumor cell targeting. Glycyrrhetinic acid, a hepatocellular carcinoma-targeting group, was covalently decorated on the surface of MSN via an amido bond. The successful synthesis of MSN-GA was validated by the results of Fourier transform infrared spectroscopy, transmission electron microscopy (TEM), and zeta potential measurement. TEM images revealed the spherical morphology and uniform size distribution of the naked MSN and MSN-GA. Curcumin (CUR), an insoluble model drug, was loaded into MSN-GA (denoted as MSN-GA-CUR) with a high-loading capacity (8.78%±1.24%). The results of the in vitro cellular experiment demonstrated that MSN-GA-CUR significantly enhanced cytotoxicity and cellular uptake toward hepatocellular carcinoma (HepG2) cells via a specific GA receptor-mediated endocytosis mechanism. The results of this study provide a promising nanoplatform for the targeting of hepatocellular carcinoma. Dove Medical Press 2017-06-12 /pmc/articles/PMC5476610/ /pubmed/28652738 http://dx.doi.org/10.2147/IJN.S135626 Text en © 2017 Lv et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Lv, Yongjiu
Li, Jingjing
Chen, Huali
Bai, Yan
Zhang, Liangke
Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier
title Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier
title_full Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier
title_fullStr Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier
title_full_unstemmed Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier
title_short Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier
title_sort glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476610/
https://www.ncbi.nlm.nih.gov/pubmed/28652738
http://dx.doi.org/10.2147/IJN.S135626
work_keys_str_mv AT lvyongjiu glycyrrhetinicacidfunctionalizedmesoporoussilicananoparticlesashepatocellularcarcinomatargeteddrugcarrier
AT lijingjing glycyrrhetinicacidfunctionalizedmesoporoussilicananoparticlesashepatocellularcarcinomatargeteddrugcarrier
AT chenhuali glycyrrhetinicacidfunctionalizedmesoporoussilicananoparticlesashepatocellularcarcinomatargeteddrugcarrier
AT baiyan glycyrrhetinicacidfunctionalizedmesoporoussilicananoparticlesashepatocellularcarcinomatargeteddrugcarrier
AT zhangliangke glycyrrhetinicacidfunctionalizedmesoporoussilicananoparticlesashepatocellularcarcinomatargeteddrugcarrier